



Supplementary Fig. 5. Cumulative incidence of secondary outcomes in sodium-glucose cotransporter-2 inhibitor (SGLT-2i) and thiazolidinedione (TZD). (A) Myocardial infarction (MI), (B) cardiovascular (CV) death, (C) 3-point major adverse cardiovascular events (MACE), and (D) heart failure (HF).